{"filing":{"accession_number":"0001640334-26-001427","cik":"0001018735","ticker":"NYMXF","company_name":"NYMOX PHARMACEUTICAL CORP","form":"6-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"nymox_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1018735/000164033426001427/nymox_6k.htm"},"events":[{"id":30556,"run_id":28004,"accession_number":"0001640334-26-001427","anchor_item_number":"EX-99.1","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This exhibit is a transcript of a special shareholders meeting held on August 28, 2026, in which the company reports official voting results on the election of five directors to the Board. The transcript explicitly discloses the vote count (47,066,029 shares in favor, 98.29% approval rate) and confirms the election of the five nominees: Dr. Russell Thomson, Dr. Kresimir Pucaj, Mr. Robert Lachance, Dr. David Morse, and Dr. Paul Averback. Board composition changes are material to investors' assessment of governance and strategic direction.","company_name":"NYMOX PHARMACEUTICAL CORP","ticker":"NYMXF","filing_date":"2026-08-31","form":"6-K","submitted_at":null,"items":[{"id":33180,"accession_number":"0001640334-26-001427","item_number":"EX-99.1","item_title":"nymox_ex991.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a transcript of a special shareholders meeting held on August 28, 2026, in which the company reports official voting results on the election of five directors to the Board. The transcript explicitly discloses the vote count (47,066,029 shares in favor, 98.29% approval rate) and confirms the election of the five nominees: Dr. Russell Thomson, Dr. Kresimir Pucaj, Mr. Robert Lachance, Dr. David Morse, and Dr. Paul Averback. Board composition changes are material to investors' assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T16:22:48.516775+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33180,"accession_number":"0001640334-26-001427","item_number":"EX-99.1","item_title":"nymox_ex991.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a transcript of a special shareholders meeting held on August 28, 2026, in which the company reports official voting results on the election of five directors to the Board. The transcript explicitly discloses the vote count (47,066,029 shares in favor, 98.29% approval rate) and confirms the election of the five nominees: Dr. Russell Thomson, Dr. Kresimir Pucaj, Mr. Robert Lachance, Dr. David Morse, and Dr. Paul Averback. Board composition changes are material to investors' assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T16:22:48.516775+00:00","company_name":"NYMOX PHARMACEUTICAL CORP","ticker":"NYMXF","filing_date":"2026-08-31"}]}